Organon has signed a commercialisation agreement with Eli Lilly and Company for two migraine medicines, Emgality (galcanezumab) and REYVOW (lasmiditan), in Europe.

Organon will exclusively supply and promote the two medicines in the region.

Lilly will serve as the marketing authorisation holder and manufacture the products.

The company will receive $50m in upfront payment and milestone payments based on product sales.

The deal will close in the first quarter of 2024.

A humanised monoclonal antibody calcitonin gene-related peptide antagonist, Emgality is indicated for migraine prophylaxis in adult patients with a minimum of four migraine days every month.

A serotonin 5-HT1F receptor agonist, REYVOW is indicated as an acute treatment for the headache phase of migraine attacks in adult patients, irrespective of aura status.

Eli Lilly and Company executive vice-president Ilya Yuffa stated: “Lilly is committed to helping people living with migraine, a debilitating neurological disease.

“We are confident this collaboration with Organon will help even more people throughout Europe gain access to our innovative migraine treatments.”

The latest deal builds on the commercial capabilities of Organon in the central nervous system disorder field.

This partnership will also bolster the company’s European product portfolio for ailments that primarily impact women.

Organon CEO Kevin Ali said: “This commercialisation agreement aligns seamlessly with Organon’s suite of central nervous system treatments in our established brands portfolio and, most importantly, it further bolsters our offerings to women, who are disproportionately impacted by migraine.

“Our strong commercial expertise and proven track record in this therapeutic area will help enable us to bring these important treatments to more patients across Europe who need them.”

Organon signed a definitive agreement for the acquisition of clinical-stage drug development company Forendo for $954m in November 2021.